Literature DB >> 31970174

Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.

Emanuela Cimpeanu1, Jibran Ahmed2, Wahib Zafar2, Adreana DeMarinis3, Svetoslav S Bardarov4, Shamim Salman5, Dennis Bloomfield3.   

Abstract

BACKGROUND: Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma (PSC), a rare, previously rapidly fatal subtype of non-small-cell lung cancer. CASE
SUMMARY: We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells. The patient was started on pembrolizumab and, after 5 cycles, there was a more than 80 percent decrease in the size of the tumor mass. Further decrease was seen at the end of 10 cycles. The patient has been tolerating pembrolizumab well, with no limiting side-effects. Fourteen months after first coming into the hospital, he remains asymptomatic.
CONCLUSION: Pembrolizumab appears as a viable emerging treatment for PSC. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Non-small-cell lung cancer; Overall survival; Pembrolizumab; Platinum-based chemotherapy; Programmed death-ligand 1; Pulmonary sarcomatoid carcinoma

Year:  2020        PMID： 31970174      PMCID： PMC6962068          DOI： 10.12998/wjcc.v8.i1.97

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN： 2307-8960            Impact factor:   1.337


  17 in total

1.  Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.

Authors:  Conor E Steuer; Madhusmita Behera; Yuan Liu; Chao Fu; Theresa W Gillespie; Nabil F Saba; Dong M Shin; Rathi N Pillai; Suchita Pakkala; Taofeek K Owonikoko; Fadlo R Khuri; Suresh S Ramalingam
Journal:  Clin Lung Cancer       Date:  2016-12-07       Impact factor: 4.785

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma.

Authors:  Yongbin Lin; Han Yang; Qingqing Cai; Daofeng Wang; Huilan Rao; Suxia Lin; Hao Long; Jianhua Fu; Lanjun Zhang; Peng Lin; Guangchuan Xu; Tiehua Rong; Xiaoxing Xiong; Guowei Ma; Ying Liang
Journal:  Am J Clin Oncol       Date:  2016-06       Impact factor: 2.339

4.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors:  Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal:  Lancet Oncol       Date:  2016-10-10       Impact factor: 41.316

5.  Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.

Authors:  Thibault Vieira; Nicolas Girard; Mony Ung; Isabelle Monnet; Aurélie Cazes; Pierre Bonnette; Michael Duruisseaux; Julien Mazieres; Martine Antoine; Jacques Cadranel; Marie Wislez
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

Review 7.  [Pulmonary sarcomatoid carcinoma].

Authors:  Martine Antoine; Thibault Vieira; Vincent Fallet; Cécile Hamard; Michael Duruisseaux; Jacques Cadranel; Marie Wislez
Journal:  Ann Pathol       Date:  2016-01-08       Impact factor: 0.407

Review 8.  Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.

Authors:  J Remon; C E Steuer; S S Ramalingam; E Felip
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

9.  The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report.

Authors:  Yoko Matsumoto; Tamaki Miura; Hajime Horiuchi; Kazuhiro Usui
Journal:  Case Rep Oncol       Date:  2017-08-10

10.  Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.

Authors:  Nagla Abdel Karim; James Schuster; Ihab Eldessouki; Ola Gaber; Tariq Namad; Jiang Wang; Changchun Xie; John C Morris
Journal:  Oncotarget       Date:  2017-12-18
View more
  4 in total

1.  Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.

Authors:  Xuewen Liu; Fang Wang; Chunwei Xu; Xinru Chen; Xue Hou; Qian Li; Pansong Li; Zhi Xie; Yongdong Liu; Lianpeng Chang; Yanfang Guan; Xuchao Zhang; Ling Yang; Hui Wang; Xin Yi; Jianjun Zhang; Xuefeng Xia; Cesar Moran; Likun Chen
Journal:  Oncogene       Date:  2020-12-03       Impact factor: 9.867

2.  Pulmonary sarcomatoid carcinoma mimicking pleural mesothelioma: A case report.

Authors:  Le Wang; Jing Zhang; Xing Chen; Maoli Liang; Shuo Li; Wei Zhou; Jie Cao
Journal:  Medicine (Baltimore)       Date:  2021-11-12       Impact factor: 1.817

3.  Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.

Authors:  Yu-Feng Li; Xin-Fei Zhao; Yue Tian; Xin-Yao Xiao; Cai-Yun Yan; Hua Shen
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

4.  Prognostic factors in patients undergoing pulmonary resection for sarcomatoid carcinomas of the lung.

Authors:  Berker Özkan; Eren Erdoğdu; Salih Duman; Fahmin Amirov; Berk Çimenoğlu; Yasemin Özlük; Murat Kara; Dilek Yılmazbayhan; Alper Toker
Journal:  Balkan Med J       Date:  2021-03       Impact factor: 2.021
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.